Castle Biosciences (CSTL) Amortization of Deferred Charges (2018 - 2020)

Castle Biosciences has disclosed Amortization of Deferred Charges across 3 years of filings, most recently posting $173000.0 for Q4 2020.

• Amortization of Deferred Charges for Q4 2020 came in at $173000.0, down 26.07% year-over-year; the trailing twelve-month figure through Sep 2021 was $173000.0 (down 80.78% YoY), and the FY2020 annual result was $839000.0, down 56.42% from the prior year.
• Amortization of Deferred Charges came in at $173000.0 for Q4 2020 at Castle Biosciences, down from $214000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $767000.0 in Q2 2019 to a low of $139273.0 in Q3 2018.
• The 3-year median for Amortization of Deferred Charges is $226000.0 (2020), against an average of $269820.2.
• Across the five-year window, Amortization of Deferred Charges soared 75.91% in 2019 and slumped 70.27% in 2020, its largest moves.
• Castle Biosciences' Amortization of Deferred Charges stood at $139929.0 in 2018, then soared by 67.23% to $234000.0 in 2019, then declined by 26.07% to $173000.0 in 2020.
• The last three Amortization of Deferred Charges figures came in at $173000.0 (Q4 2020), $214000.0 (Q3 2020), and $228000.0 (Q2 2020), per Business Quant data.